The Role of Angiogenesis in Cancer Treatment

• Published in: Biomedicines Vol. 5; no. 2; p. 34
• Main Authors: Rajabi, Mehdi, Mousa, Shaker A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.06.2017; MDPI
• Subjects: Angiogenesis; Blood vessels; Cancer; Cancer therapies; Chemotherapy; Developmental stages; Endothelial cells; Extracellular matrix; Growth factors; Porosity; Proteins; Review; Smooth muscle; Tumors; pathological angiogenesis; tyrosine kinase inhibitors; endothelial cells; physiological angiogenesis; pericyte; vascular growth factors; anti-angiogenesis; anti-VEGF; matrix metalloproteinase; anti-integrin; integrin; pro-angiogenesis
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines5020034

A number of anti-angiogenesis drugs have been FDA-approved and are being used in cancer treatment, and a number of other agents are in different stages of clinical development or in preclinical evaluation. However, pharmacologic anti-angiogenesis strategies that arrest tumor progression might not be enough to eradicate tumors. Decreased anti-angiogenesis activity in single mechanism-based anti-angiogenic strategies is due to the redundancy, multiplicity, and development of compensatory mechanism by which blood vessels are remodeled. Improving anti-angiogenesis drug efficacy will require identification of broad-spectrum anti-angiogenesis targets. These strategies may have novel features, such as increased porosity, and are the result of complex interactions among endothelial cells, extracellular matrix proteins, growth factors, pericyte, and smooth muscle cells. Thus, combinations of anti-angiogenic drugs and other anticancer strategies such as chemotherapy appear essential for optimal outcome in cancer patients. This review will focus on the role of anti-angiogenesis strategies in cancer treatment.